Alberta's Tomorrow Project, Canada

Certification Status: Approved

Registration Status: Completed

Objective: As Albertaâ€™s largest health research study, ATP aims to reveal what causes and what may prevent cancer and chronic diseases. Following the health of 55,000 men and women for the next 50 years, this long-term cohort study provides exceptional depth and breadth of detailed information to researchers around the world. Thanks to hundreds of thousands of pieces of data and biological samples, scientists will be able to explore how lifestyle, genetics and environment influence the health of generations to come. In 2008, ATP joined a nation-wide research platform called the Canadian Partnership for Tomorrow Project (CPTP) representing more than 300,000 participants from five provincial cohorts: Alberta, British Columbia, Ontario, Quebec and the Atlantic provinces (Prince Edward Island, New Brunswick, Newfoundland and Labrador, and Nova Scotia). Together, the consortium of five regional studies will provide not only greater statistical power for research, but an opportunity to examine geographical trends in health and wellbeing across Canadaâ€™s vast landscape.

Registered Biobank Name	Alberta's Tomorrow Project
Biobank Leader	Gillian MacNevin, Bioresource Advisor
Country	Canada
Email for biobank inquiries	ATP.Research@albertahealthservices.ca
Principal Investigator	Dr. Jennifer Vena, Scientific Director
Website	myatp.ca
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper	Poly - Collection aimed at supporting undetermined, multiple users with ethics approved research projects, through a defined access/application mechanism.

Biospecimen Collected:

Cohort Highlights

100 cases Next Generation Sequencing assay to detect all classes of genetic variant in Lung Cancer using a single Diagnostic test.
200 cases Colorectal TMA for QC purposes in support of study of tumor infiltrating lymphocytes in ovarian cancer tissues.
Build 300 cases breast cancer TMA containing primary tumour and matched metastatic LN for various subtypes (luminal, HER2, Triple negative). Start with Triple negatives.
125 cases Breast tumour and metastatic lymph nodes in breast cancer cases with outcomes of metastasis to lung or bone.
100 cases of rare tumours - fibrolamellar hepatocellular carcinoma. FFPE, frozen, BC.
200 cases of FFPE tissue sections from breast, lung adenocarcinoma, and lung squamous cell carcinoma with matching normal tissue (only pathology data requested).